Astrazeneca (AZN) Non-Current Debt (2009 - 2026)

Astrazeneca has reported Non-Current Debt for 18 years, with the latest figure at -$5.8 billion in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 10.54% year-over-year to -$5.8 billion in Q2 2026; TTM through Jun 2026 was -$5.8 billion, a 10.54% increase from a year earlier, with the FY2025 full-year figure at -$3.1 billion, down 32.82% from the prior year.
• Non-Current Debt was -$5.8 billion for Q2 2026 at Astrazeneca, up from -$7.6 billion in the prior quarter.
• The five-year high for Non-Current Debt was -$1.3 billion in Q3 2024, with the low at -$7.6 billion in Q1 2026.
• Average Non-Current Debt over 5 years is -$4.5 billion, with a median of -$5.1 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt surged 76.68% in 2024, then plunged 392.74% in 2025.
• Over 5 years, Non-Current Debt stood at -$5.3 billion in 2022, then advanced by 3.48% to -$5.1 billion in 2023, then soared by 54.44% to -$2.3 billion in 2024, then sank by 32.82% to -$3.1 billion in 2025, then slumped by 87.11% to -$5.8 billion in 2026.
• The last three Non-Current Debt figures came in at -$5.8 billion (Q2 2026), -$7.6 billion (Q1 2026), and -$3.1 billion (Q4 2025), per Business Quant data.